China Biologic Products, Inc. received permission from the SFDA to begin a clinical trial of its new Human Coagulation Factor VIII product (FVIII), a coagulation treatment for hemophilia and mass hemorrhaging. China Biologic focuses on plasma-based products. Because plasma has been in short supply in China, prices for all plasma-based products have been high, and China Biologic’s financial fortunes have risen. More details...

Stock Symbol: (OTCBB: CBPO)